The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. [electronic resource]
Producer: 20110222Description: 394-9 p. digitalISSN:- 2152-2669
- Adult
- Aged
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Drug Resistance, Neoplasm
- Female
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- Harringtonines -- therapeutic use
- Homoharringtonine
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Middle Aged
- Protein Kinase Inhibitors -- therapeutic use
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- therapeutic use
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.